U.S. Markets open in 3 hrs 52 mins
  • S&P Futures

    3,604.00
    +28.00 (+0.78%)
     
  • Dow Futures

    29,847.00
    +301.00 (+1.02%)
     
  • Nasdaq Futures

    11,942.75
    +37.50 (+0.31%)
     
  • Russell 2000 Futures

    1,842.50
    +25.40 (+1.40%)
     
  • Crude Oil

    43.54
    +0.48 (+1.11%)
     
  • Gold

    1,819.60
    -18.20 (-0.99%)
     
  • Silver

    23.39
    -0.24 (-1.03%)
     
  • EUR/USD

    1.1888
    +0.0042 (+0.3566%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.16
    -1.54 (-6.50%)
     
  • GBP/USD

    1.3356
    +0.0034 (+0.2524%)
     
  • USD/JPY

    104.2470
    -0.2410 (-0.2306%)
     
  • BTC-USD

    18,823.52
    +371.56 (+2.01%)
     
  • CMC Crypto 200

    372.92
    +11.49 (+3.18%)
     
  • FTSE 100

    6,392.86
    +59.02 (+0.93%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Recap: TELA Bio Q3 Earnings

Benzinga Insights
·1 min read

Shares of TELA Bio (NASDAQ:TELA) were flat after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 97.65% over the past year to ($0.53), which missed the estimate of ($0.49).

Revenue of $5,313,000 higher by 33.73% year over year, which beat the estimate of $4,580,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

TELA Bio hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 11, 2020

View more earnings on TELA

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/4ajr9xe6

Technicals

Company's 52-week high was at $23.55

Company's 52-week low was at $5.25

Price action over last quarter: Up 18.62%

Company Description

TELA Bio Inc is a United States-based medical technology company. It is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.